Menu
FDA DECISION ·
Truqap + abiraterone + prednisone
capivasertib with abiraterone and prednisone · AstraZeneca
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
Adults with metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with PTEN deficiency identified by an FDA-authorized test.
LAMPGEN ANALYSIS
Why it matters
This introduces PTEN deficiency as a way to select patients for an AKT inhibitor regimen in earlier metastatic prostate cancer.
What research teams should watch
Confirm the PTEN assay and scoring result. Build glucose monitoring and other regimen safety checks into the documentation for patients receiving the combination.
Clinical operations takeaway
Build specimen status, the assay report, and the review handoff into the screening checklist. Define who follows up when a report is missing or the result needs clarification.
Plan biomarker screening and specimen workflowsPRIMARY RECORDS